VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vacci… Read more
Market Cap & Net Worth: VBI Vaccines Inc. (VBIVQ)
VBI Vaccines Inc. (NASDAQ:VBIVQ) has a market capitalization of $4.69 ($4.69) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #50845 globally and #15608 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VBI Vaccines Inc.'s stock price $0.00 by its total outstanding shares 9373 (9.37K).
VBI Vaccines Inc. Market Cap History: 2015 to 2025
VBI Vaccines Inc.'s market capitalization history from 2015 to 2025. Data shows change from $1.46 Million to $4.69 (-75.46% CAGR).
VBI Vaccines Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VBI Vaccines Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
VBI Vaccines Inc.'s market cap is 0.00 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $773.27K | $1.06 Million | -$46.23 Million | 0.73x | N/A |
| 2021 | $657.98K | $631.00K | -$69.75 Million | 1.04x | N/A |
| 2022 | $109.66K | $1.08 Million | -$113.30 Million | 0.10x | N/A |
| 2023 | $5.53K | $8.68 Million | -$92.84 Million | 0.00x | N/A |
Competitor Companies of VBIVQ by Market Capitalization
Companies near VBI Vaccines Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to VBI Vaccines Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VBI Vaccines Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, VBI Vaccines Inc.'s market cap moved from $1.46 Million to $ 4.69, with a yearly change of -75.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.69 | 0.00% |
| 2024 | $4.69 | -99.92% |
| 2023 | $5.53K | -94.96% |
| 2022 | $109.66K | -83.33% |
| 2021 | $657.98K | -14.91% |
| 2020 | $773.27K | +99.28% |
| 2019 | $388.04K | -13.75% |
| 2018 | $449.90K | -62.53% |
| 2017 | $1.20 Million | +37.74% |
| 2016 | $871.69K | -40.38% |
| 2015 | $1.46 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 9th, 2026 the market cap of VBI Vaccines Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.69 USD |
| MoneyControl | $4.69 USD |
| MarketWatch | $4.69 USD |
| marketcap.company | $4.69 USD |
| Reuters | $4.69 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.